1 / 4

With support from the TB Alliance

With support from the TB Alliance. P edi a tric TB R&D I n v e s tments b y R esea r ch Category 2 0 12 T otal: $1 0 , 2 7 8, 8 7 5. Basic Scien c e $ 814, 3 56 (8%). Ope r a tional R esea r ch $965 , 185 (9%). Drugs $3,81 9 , 1 0 2 ( 3 7%). Diagnostics $1 , 0 1 7 , 160 (10 % ).

blade
Download Presentation

With support from the TB Alliance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. With support from the TB Alliance

  2. Pediatric TB R&D Investments by Research Category 2012 Total: $10,278,875 Basic Science$814,356 (8%) Operational Research $965,185 (9%) Drugs $3,819,102 (37%) Diagnostics $1,017,160 (10%) Vaccines $3,663,074 (36%)

  3. 2012 Pediatric TB R&D Funders by Rank and Compared with Prior Years Percentage of 2012 Total R&D Funding Allocated to Pediatrics 2012 Pediatric TB R&D Funding 2010 Pediatric TB R&D Funding 2012 Total TB R&D Funding 2011Pediatric TB R&D Funding 2012 Rank Funding Organization Funder Type 1 U.K. Medical Research Council P $2,644,610 $3,111,533 $408,718 $14,790,087 17.9 Other National Institutes of Health P $2,624,745 $1,917,849 $1,772,537 $36,646,883 7.2 Institutes and Centers* 3 Company X C $1,718,595 N/A N/A $22,844,099 7.5 4 U.S. National Institute of Allergy and Infectious Diseases* P $954,061 $532,394 $554,003 $169,092,971 0.6 5 Wellcome Trust F $551,017 $2,606,924 $322,682 $13,418,817 4.1 6 Company V C $481,080 N/A N/A $4,297,934 11.2 U.S. President’s Emergency P $450,000 $0 $0 $6,606,609 6.8 Plan for AIDS Relief P= public-sector R&D agency; C= Corporation/private sector; M= Multilateral; F=Foundation/philanthropy; P-D= Public-sector development agency *TAG reports National Institutes of Health investments in three categories: 1) National Institute of Allergy and Infectious Diseases—the largest investor in TB R&D overall; 2) the National Health, Lung and Blood Institute—which did not document investments in pediatric TB R&D; and 3) other NIH institutes and centers. Note: This table records contributions made only by funders investing in pediatric TB R&D in 2012.

  4. 2012 Pediatric TB R&D Funders by Rank and Compared with Prior Years (continued) Percentage of 2012 Total R&D Funding Allocated to Pediatrics 2012 Pediatric TB R&D Funding 2010 Pediatric TB R&D Funding 2012 Total TB R&D Funding 2011Pediatric TB R&D Funding 2012 Rank Funding Organization Funder Type 8 Canadian Institutes P $326,268 $661,616 N/A $6,017,561 5.4 of Health Research 9 Australian National Health P $166,738 $295,363 $153,590 $4,060,791 4.1and Medical Research Council 10 Danish International P-D $154,993 N/A N/A $323,250 47.9 Development Agency 11 World Health Organization M $85,260 $0 $0 $1,707,923 5.0 12 U.S. Agency for P-D $50,000 N/A N/A $12,174,064 0.4 International Development 13 Norwegian Knowledge Centre P $48,460 N/A N/A $48,460 100.0for the Health Services 14 Indian Council of Medical Research P $23,047 N/A N/A $7,131,390 0.3   Grand Total   $10,278,875       P= public-sector R&D agency; C= Corporation/private sector; M= Multilateral; F=Foundation/philanthropy; P-D= Public-sector development agency *TAG reports National Institutes of Health investments in three categories: 1) National Institute of Allergy and Infectious Diseases—the largest investor in TB R&D overall; 2) the National Health, Lung and Blood Institute—which did not document investments in pediatric TB R&D; and 3) other NIH institutes and centers. Note: This table records contributions made only by funders investing in pediatric TB R&D in 2012.

More Related